Jazz Pharmaceuticals PLC (JAZZ)
128.44
-0.47
(-0.36%)
USD |
NASDAQ |
Jun 07, 16:00
128.44
0.00 (0.00%)
After-Hours: 16:00
Jazz Pharmaceuticals Enterprise Value: 12.80B for June 6, 2023
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 06, 2023 | 12.80B |
| June 05, 2023 | 12.86B |
| June 02, 2023 | 12.77B |
| June 01, 2023 | 12.82B |
| May 31, 2023 | 12.76B |
| May 30, 2023 | 12.67B |
| May 26, 2023 | 12.61B |
| May 25, 2023 | 12.72B |
| May 24, 2023 | 12.82B |
| May 23, 2023 | 12.90B |
| May 22, 2023 | 13.06B |
| May 19, 2023 | 13.15B |
| May 18, 2023 | 12.99B |
| May 17, 2023 | 13.01B |
| May 16, 2023 | 12.94B |
| May 15, 2023 | 13.17B |
| May 12, 2023 | 13.24B |
| May 11, 2023 | 13.33B |
| May 10, 2023 | 13.29B |
| May 09, 2023 | 13.22B |
| May 08, 2023 | 13.43B |
| May 05, 2023 | 13.48B |
| May 04, 2023 | 13.31B |
| May 03, 2023 | 13.30B |
| May 02, 2023 | 13.32B |
| Date | Value |
|---|---|
| May 01, 2023 | 13.60B |
| April 28, 2023 | 13.54B |
| April 27, 2023 | 13.45B |
| April 26, 2023 | 13.38B |
| April 25, 2023 | 13.59B |
| April 24, 2023 | 13.80B |
| April 21, 2023 | 13.86B |
| April 20, 2023 | 13.83B |
| April 19, 2023 | 13.84B |
| April 18, 2023 | 13.74B |
| April 17, 2023 | 13.89B |
| April 14, 2023 | 13.86B |
| April 13, 2023 | 13.88B |
| April 12, 2023 | 13.77B |
| April 11, 2023 | 13.94B |
| April 10, 2023 | 13.91B |
| April 06, 2023 | 13.97B |
| April 05, 2023 | 13.88B |
| April 04, 2023 | 13.77B |
| April 03, 2023 | 13.86B |
| March 31, 2023 | 13.92B |
| March 30, 2023 | 14.02B |
| March 29, 2023 | 13.93B |
| March 28, 2023 | 13.87B |
| March 27, 2023 | 13.92B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
5.455B
Minimum
Mar 23 2020
17.14B
Maximum
Jul 12 2021
10.88B
Average
9.910B
Median
Oct 15 2018
Enterprise Value Benchmarks
| Alkermes PLC | 4.742B |
| Perrigo Co PLC | 8.089B |
| Horizon Therapeutics PLC | 23.04B |
| Iterum Therapeutics PLC | -6.472M |
| Mallinckrodt PLC | 2.625B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 69.42M |
| Revenue (Quarterly) | 892.81M |
| Total Expenses (Quarterly) | 765.76M |
| EPS Diluted (Quarterly) | 1.04 |
| Gross Profit Margin (Quarterly) | 85.59% |
| Profit Margin (Quarterly) | 7.78% |
| Earnings Yield | -1.98% |
| Operating Earnings Yield | 6.53% |
| Normalized Earnings Yield | 2.846 |